Equillium (EQ) Price & Analysis

Compare

754 Followers

EQ Stock Chart & Stats

$1.92

-$0.05(-6.85%)

At close: Jan 08 4:00 PM EST

$1.92

-$0.05(-6.85%)

Day’s Range― - ―

52-Week Range$0.27 - $2.35

Previous CloseN/A

Volume484.47K

Average Volume (3M)883.61K

Market Cap

$116.92M

Enterprise Value$35.83M

Total Cash (Recent Filing)$33.12M

Total Debt (Recent Filing)$745.00K

Price to Earnings (P/E)―

Beta-0.15

Next Earnings

Mar 26, 2026

EPS Estimate

-0.06

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.06

Shares Outstanding60,893,284

10 Day Avg. Volume862,141

30 Day Avg. Volume883,611

Financial Highlights & Ratios

PEG Ratio0.08

Price to Book (P/B)1.39

Price to Sales (P/S)0.64

P/FCF Ratio-1.38

Enterprise Value/Market Cap0.31

Enterprise Value/Revenue8.16

Enterprise Value/Gross Profit8.33

Enterprise Value/Ebitda-1.45

Forecast

1Y Price Target

$5.00

Price Target Upside160.42% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)-0.23

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Analyst Coverage And Market OpportunityAnalyst initiates coverage with a Buy rating citing unmet needs in the inflammatory bowel disease market and the potential for EQ504 to complement or replace existing therapies.

Mechanism Of ActionEQ504 is a chemically optimized aryl hydrocarbon receptor modulator that retained potency of natural molecules and showed protective effects in ulcerative colitis models, supporting potential therapeutic relevance.

Targeted FormulationDevelopment of an enteric coating to target drug delivery to the colon could enhance local exposure and improve therapeutic benefit for inflammatory bowel disease patients.

Bears Say

Clinical And Regulatory UncertaintyUncertainty around human dosing, safety profile, and regulatory expectations for a novel AhR-targeting oral therapy could extend development timelines and increase costs.

Preclinical Development RiskEQ504 remains in preclinical development, which increases scientific and clinical risk because human safety and efficacy have not been established.

Translation Risk From Models To HumansPositive signals in laboratory disease models and activity of natural AhR modulators may not translate into meaningful clinical benefit in human patients, creating uncertainty for program success.

Equillium News

Equillium initiated with a Buy at Stifel

Stifel analyst Alex Thompson initiated coverage of Equillium (EQ) with a Buy rating and $5 price target Despite...

7d ago

Equillium Reports Q3 Loss Amid Strategic Focus

Equillium ( ($EQ) ) has released its Q3 earnings. Here is a breakdown of the information Equillium presented...

4M ago

Equillium files $250M mixed securities shelf

17:00 EST Equillium (EQ) files $250M mixed securities shelf Published first on TheFly – the ultimate source for...

4M ago

Equillium Announces Board Restructuring and Biocon Agreement Termination

The latest update is out from Equillium ( ($EQ) ). On September 30, 2025, Equillium announced significant changes...

5M ago

Equillium terminates collaboration, license agreement with Biocon

The company said, “As previously announced, Equillium (EQ) had no further intention to continue development of itolizumab, therefore...

5M ago

Equillium Files Prospectus for $75 Million Stock Sale

Equillium ( ($EQ) ) just unveiled an update. On September 19, 2025, Equillium, Inc. announced the filing of...

5M ago

Equillium files to sell 52.63M shares of common stock for holders

17:01 EDT Equillium (EQ) files to sell 52.63M shares of common stock for holders Published first on TheFly...

6M ago

Equillium Regains Nasdaq Compliance with Bid Price Rule

Equillium ( ($EQ) ) has provided an update. On August 29, 2025, Equillium, Inc. announced that it has...

6M ago

Equillium price target lowered to $4 from $8 at Jefferies

Jefferies lowered the firm’s price target on Equillium (EQ) to $4 from $8 and keeps a Buy rating...

6M ago

Equillium’s Strategic Moves and Financial Position Lead to Hold Rating Amid Clinical Trial Uncertainties

Leerink Partners analyst Thomas Smith has maintained their neutral stance on EQ stock, giving a Hold rating on...

7M ago

3 Penny Stocks to Watch Now, 8/12/25

Equillium, Bluejay Diagnostics, and Entero Therapeutics are the 3 Penny Stocks to watch on August 12, 2025, based on TipRanks’ Penny...

7M ago

BJDX

Equillium Stock (EQ) Rockets 140% on $50M Private Placement

Equillium stock soared on Monday after the company announced a $50 million private placement. ...

7M ago

Morning News Wrap-Up: Monday’s Biggest Stock Market Stories!

Monday is here and with it comes loads of stock market stories that traders need to start the week with! ...

7M ago

Equillium Secures $30 Million in Private Placement

Equillium ( ($EQ) ) has issued an update. On August 10, 2025, Equillium, Inc. entered into a Securities...

7M ago

EQ FAQ

What was Equillium Inc’s price range in the past 12 months?

Equillium Inc lowest stock price was $0.27 and its highest was $2.35 in the past 12 months.

What is Equillium Inc’s market cap?

Equillium Inc’s market cap is $116.92M.

When is Equillium Inc’s upcoming earnings report date?

Equillium Inc’s upcoming earnings report date is Mar 26, 2026 which is in 23 days.

How were Equillium Inc’s earnings last quarter?

Equillium Inc released its earnings results on Nov 13, 2025. The company reported -$0.06 earnings per share for the quarter, beating the consensus estimate of -$0.07 by $0.01.

Is Equillium Inc overvalued?

According to Wall Street analysts Equillium Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Equillium Inc pay dividends?

Equillium Inc does not currently pay dividends.

What is Equillium Inc’s EPS estimate?

Equillium Inc’s EPS estimate is -0.06.

How many shares outstanding does Equillium Inc have?

Equillium Inc has 60,893,284 shares outstanding.

What happened to Equillium Inc’s price movement after its last earnings report?

Equillium Inc reported an EPS of -$0.06 in its last earnings report, beating expectations of -$0.07. Following the earnings report the stock price went up 23.81%.

Which hedge fund is a major shareholder of Equillium Inc?

Currently, no hedge funds are holding shares in EQ

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Equillium Stock Smart Score

Outperform

Fundamentals

Return on Equity

-90.24%

Trailing 12-Months

Asset Growth

-71.07%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Equillium Inc

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

Equillium (EQ) Earnings & Revenues

Historic Earnings Reports

EQ Stock 12 Month Forecast

Average Price Target

$5.00

▲(160.42% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"$6","-1":"-$1","0.75":"$0.75","2.5":"$2.5","4.25":"$4.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$5.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$5.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$5.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0.75,2.5,4.25,6],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.51,1.7784615384615385,2.046923076923077,2.315384615384615,2.583846153846154,2.8523076923076927,3.1207692307692305,3.3892307692307693,3.657692307692308,3.926153846153846,4.194615384615385,4.463076923076923,4.731538461538461,{"y":5,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.51,1.7784615384615385,2.046923076923077,2.315384615384615,2.583846153846154,2.8523076923076927,3.1207692307692305,3.3892307692307693,3.657692307692308,3.926153846153846,4.194615384615385,4.463076923076923,4.731538461538461,{"y":5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.51,1.7784615384615385,2.046923076923077,2.315384615384615,2.583846153846154,2.8523076923076927,3.1207692307692305,3.3892307692307693,3.657692307692308,3.926153846153846,4.194615384615385,4.463076923076923,4.731538461538461,{"y":5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.64,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.76,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.5,"date":1743465600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.41,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.37,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.32,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.71,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.72,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.48,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.41,"date":1761955200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.86,"date":1764547200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 36, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.55,"date":1767225600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 51, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.51,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 43, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >